Lifera And Novo Nordisk Launch GLP-1 Localisation Initiative In Saudi Arabia

In a groundbreaking move for Saudi Arabia’s pharmaceutical sector, Novo Nordisk has entered into a Memorandum of Understanding (MoU) with Lifera, a biopharmaceutical entity under the Saudi Public Investment Fund, aiming to commence local production of semaglutide GLP-1, a leading medication for managing excess weight.

The planned local production of semaglutide GLP-1 in Saudi Arabia is poised to significantly improve healthcare access for individuals battling chronic diseases. It aims to fortify the nation's independence in pharmaceutical production and foster innovation within the local healthcare sector. This strategic move not only aims at enhancing medical access but also supports the broader vision of economic diversification and skill development within the Kingdom.

The agreement was formalised in the presence of Eng. Khalid bin Abdulaziz Al-Falih, the Minister of Investment, alongside high-ranking officials and representatives from both organizations. This partnership underscores a mutual commitment to bolstering the healthcare landscape in Saudi Arabia by advancing local capabilities in the production of critical medicines.

Addressing the collaboration, Mike Dostar, Executive Vice President of International Operations at Novo Nordisk, emphasized the MoU's alignment with the company's dedication to supporting individuals with chronic diseases within the Kingdom. "This MoU is a testament to our long-standing commitment to people living with chronic diseases in Saudi Arabia," Dostar stated.

He highlighted the initiative's goal to broaden the availability of Novo Nordisk's transformative treatments, thereby providing relief to a larger portion of the population affected by chronic conditions, in parallel with fostering the local pharmaceutical industry and its workforce.

Melvin D’Souza, General Manager of Novo Nordisk in Saudi Arabia, shed light on the broader implications of the MoU. He pointed out how this initiative is part of Novo Nordisk’s broader strategy to enhance healthcare accessibility and address the challenges posed by chronic diseases in the Kingdom.

"Through this MoU, Novo Nordisk aims to contribute to improving access to essential therapeutic solutions in the Kingdom, accelerating access to care for individuals with chronic diseases, and ultimately reducing the high costs of long-term healthcare associated with chronic diseases," D’Souza explained.

He also shared the company's ambition to significantly increase the number of patients reached with their diabetes and obesity treatments by 2030, highlighting the anticipated influx of pharmaceutical innovations and the focus on sustainable growth.

Furthermore, the MoU lays the groundwork for Novo Nordisk and Lifera to build local manufacturing capacities for GLP-1 semaglutide treatments in Saudi Arabia, a move that promises to revolutionize the treatment landscape for obesity and related chronic diseases in the region.

With the introduction of Wegovy® anticipated in 2025, this partnership aims to make advanced medical treatments more accessible in both the public and private healthcare sectors across Saudi Arabia.